Jag Capital Management LLC Has $243,000 Stake in Axon Enterprise, Inc $AXON

Jag Capital Management LLC reduced its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 96.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 572 shares of the biotechnology company’s stock after selling 13,709 shares during the period. Jag Capital Management LLC’s holdings in Axon Enterprise were worth $243,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Evergreen Capital Management LLC grew its holdings in Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares in the last quarter. CWA Asset Management Group LLC boosted its holdings in Axon Enterprise by 5.2% during the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 19 shares during the last quarter. Synergy Financial Group LTD boosted its holdings in Axon Enterprise by 1.4% during the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 19 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after acquiring an additional 19 shares in the last quarter. Finally, Certuity LLC grew its stake in shares of Axon Enterprise by 5.1% in the 4th quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 23 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $541.75 on Friday. The firm has a market capitalization of $43.67 billion, a PE ratio of 217.57, a P/E/G ratio of 11.04 and a beta of 1.38. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average price of $469.54 and a two-hundred day moving average price of $481.68. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.01. The company had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.47 earnings per share. Equities analysts forecast that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive owned 49,710 shares in the company, valued at $24,855,000. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 20,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $10,000,000.00. Following the sale, the chief executive officer owned 3,060,997 shares in the company, valued at approximately $1,530,498,500. This represents a 0.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 58,989 shares of company stock worth $30,527,983 in the last three months. Insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on AXON shares. JPMorgan Chase & Co. raised their price target on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. TD Cowen reduced their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Needham & Company LLC increased their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Monday, July 6th. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Finally, Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Fifteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $725.25.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.